Featured Research

from universities, journals, and other organizations

Help for patients with tuberous sclerosis

Date:
February 12, 2013
Source:
Charité - Universitätsmedizin Berlin
Summary:
Scientists have developed a new therapy for patients suffering from renal tumors associated with the rare genetic disease tuberous sclerosis (TSC). The researchers have succeeded in markedly reducing the tumor volume in TSC patients by using the drug Everolimus.

In collaboration with the Berlin TSC Centre, Charité -- Universitätsmedizin Berlin has developed a new therapy for patients suffering from renal tumours associated with the rare genetic disease tuberous sclerosis (TSC). The researchers have succeeded in markedly reducing the tumour volume in TSC patients by using the drug Everolimus.

Related Articles


The results of the study appear in the medical journal The Lancet.

Tuberous sclerosis is a rare genetic disease that can affect many organs, including the kidneys, the brain, the skin, the lungs and the heart. The disease is characterised by a malfunctioning regulation of the so-called mTOR pathway. mTOR is an integral component of a protein complex that integrates different cell pathways, regulates the production of proteins and thus controls cell growth and the cell cycle. The malfunctioning regulation of the mTOR pathway leads to excessive cell growth, which, in turn, results in the formation of benign tumours on the skin and in the body. The constant growth, however, may cause severe haemorrhages and the suppression of other organs. In addition, renal tumours may trigger serious renal problems.

"This worldwide clinical trial for regulatory approval has for the first time shown that the use of the drug Everolimus, a so-called mTOR inhibitor, can substantially reduce the tumour volume in patients with renal tumours triggered by the genetic disease tuberous sclerosis," states Prof. Klemens Budde, Senior Physician in the Medical Department, Division of Nephrology at Campus Charité Mitte and responsible author of the study. Within half a year, the tumour volume in nearly half the patients affected had been reduced by more than 50 percent. In addition, the drug had beneficial effects on the skin symptoms of a quarter of the patients.

This new medication could therefore offer an effective alternative to the operative removal of the kidneys in the long term, the Lancet editorial emphasises. The development of an approved drug therapy for a rare genetic disease is an outstanding example of years of basic research paying off with the emergence of new targeted therapy approaches. As in many diseases the mTOR pathway is defective, mTOR inhibitors can be used, for instance, with organ transplant patients, malignant renal tumours, rare neuroendocrine tumours and even with breast cancer.

"A worldwide study for a rare disease such as TSC would scarcely have been possible without the excellent collaboration with the researchers in the interdisciplinary Berlin Tuberous Sclerosis Centre," stresses Dr. Christoph Herztberg, Head of the TSC Centre Berlin at the Neukölln Vivantes Clinic.


Story Source:

The above story is based on materials provided by Charité - Universitätsmedizin Berlin. Note: Materials may be edited for content and length.


Journal Reference:

  1. John J Bissler, J Christopher Kingswood, Elżbieta Radzikowska, Bernard A Zonnenberg, Michael Frost, Elena Belousova, Matthias Sauter, Norio Nonomura, Susanne Brakemeier, Petrus J de Vries, Vicky H Whittemore, David Chen, Tarek Sahmoud, Gaurav Shah, Jeremie Lincy, David Lebwohl, Klemens Budde. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. The Lancet, 2013; DOI: 10.1016/S0140-6736(12)61767-X

Cite This Page:

Charité - Universitätsmedizin Berlin. "Help for patients with tuberous sclerosis." ScienceDaily. ScienceDaily, 12 February 2013. <www.sciencedaily.com/releases/2013/02/130212100426.htm>.
Charité - Universitätsmedizin Berlin. (2013, February 12). Help for patients with tuberous sclerosis. ScienceDaily. Retrieved March 5, 2015 from www.sciencedaily.com/releases/2013/02/130212100426.htm
Charité - Universitätsmedizin Berlin. "Help for patients with tuberous sclerosis." ScienceDaily. www.sciencedaily.com/releases/2013/02/130212100426.htm (accessed March 5, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, March 5, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Adults Only Get The Flu Twice A Decade, Researchers Say

Adults Only Get The Flu Twice A Decade, Researchers Say

Newsy (Mar. 4, 2015) — Researchers found adults only get the flu about once every five years. Scientists analyzed how a person&apos;s immunity builds up over time as well. Video provided by Newsy
Powered by NewsLook.com
New Hormone Could Protect Against Diabetes And Weight Gain

New Hormone Could Protect Against Diabetes And Weight Gain

Newsy (Mar. 4, 2015) — A newly discovered hormone mimics the effects of exercise, protecting against diabetes and weight gain. Video provided by Newsy
Powered by NewsLook.com
Mount Everest Has a Poop Problem

Mount Everest Has a Poop Problem

Buzz60 (Mar. 4, 2015) — With no bathrooms to use, climbers of Mount Everest have been leaving human waste on the mountain for years, and it&apos;s becoming a health issue. Mike Janela (@mikejanela) has more. Video provided by Buzz60
Powered by NewsLook.com
The Best Tips to 'Skinny' Your Home

The Best Tips to 'Skinny' Your Home

Buzz60 (Mar. 4, 2015) — If you&apos;re looking to reach your health goals this season, there are a few simple tips to help you spring clean your space and improve your nutrition. Krystin Goodwin (@krystingoodwin) has the skinny on keeping a healthy home. Video provided by Buzz60
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins